Modified Marek's disease virus, and vaccines made therefrom
AssigneeBoehringer Ingelheim Animal Health USA Inc.
InventorsJoyce Pritchard, Teshome Mebatsion, Michel Bublot
Life of this patent
Estimating the term…
Abstract
The present invention provides an effective vaccine for Marek's disease, which may be prepared using a recombinant Marek's Disease Virus (MDV), strain CVI988, having been transformed with a foreign DNA construct that includes a long terminal repeat sequence of a reticuloendotheliosis virus. This safe viral agent elicits a highly protective immune response in a chicken against virulent MDV challenge without causing a significant degree of pathogenicity. Suitable formulations of the vaccine for use in chickens include an effective immunization dosage of this novel viral agent, along with a pharmaceutically acceptable carrier or diluent.
Claims15
A method of eliciting a protective immune response against Marek's Disease virus (MDV) in an avian, comprising administering to the avian a therapeutically effective amount of a composition,
- wherein the composition comprises a viral agent stably transformed with a foreign DNA construct comprising a long terminal repeat (LTR) sequence of a reticuloendotheliosis virus,
- wherein the viral agent is a clonal virus, and not a mixed population of parental and recombinant virus, and
- wherein the viral agent is a CVI988/X MDV SR-1 RN1250 deposited at ATCC under the accession number PTA-122066.
A method of making a viral agent effective for protecting an avian-against Marek's disease comprising transforming a Marek's Disease virus (DMV) strain CVI988 with a foreign DNA construct which comprises a long terminal repeat (LTR) sequence of a reticuloendotheliosis virus, wherein the viral agent is a clonal virus, and not a mixed population of parental and recombinant virus, and wherein the viral agent is a CVI988/X MDV SR-1 RN1250 deposited at ATCC under the accession number PTA-122066.
A Marek's disease virus (MDV) stably transformed with a foreign DNA construct comprising a long terminal repeat (LTR) sequence of a reticuloendotheliosis virus, wherein the MDV is a clonal virus, and not a mixed population of parental and recombinant virus, and wherein the MDV is CVI988/X MDV SR-1 RN1250 deposited at ATCC under the accession number PTA-122066.
Dependencies are inferred from the claim text.